There is typically a discount for drugs or devices still in clinical stage of maybe 75-80% depending on what the chance of approval is determined to be by the company proposing the buyout. The global TAVR market in 2025 is expected to be around $6 billion USD with a CAGR of 18% going forward so if you figure a 10% DurAVR market share in 2025, 20% in 2026 and 50% for the next 7 years: that's a revenue potential of very roughly about $23 billion USD for 7 years. So 75% of that would be over $17 billion in potential revenue. Plus you figure in market share that one of the current big two TAVR companies would lose and the possibility of expanding the market with younger patients when using DurAVR...and perhaps a bidding war?
$5 billion USD would seem to be the absolute floor for a buyout offer and that's a $355 AUD share price currently, but it could go a good bit higher. I'd have a tough time voting against something like that if it were to materialize.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)